Secondly, in vitro functional validation experiments will be conducted in CHI3L1 overexpressed synovial fibroblasts and peripheral blood mononuclear cell-derived macrophages to investigate whether glibenclamide inhibits the pathological processes related to rheumatoid arthritis (RA) by targeting CHI3L1. This evidence concerns the gene CHI3L1 and rheumatoid arthritis.